Cargando…

Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer

Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Quanxia, Meng, Ziyuan, Yu, Yuanyuan, Jiang, Feng, Guan, Daogang, Liang, Chao, Zhou, Junwei, Lu, Aiping, Zhang, Ge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187895/ https://www.ncbi.nlm.nih.gov/pubmed/27983617 http://dx.doi.org/10.3390/ijms17122095

Ejemplares similares

Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers
por: Yu, Yuanyuan, et al.
Publicado: (2016)

Prodrug Strategies for Paclitaxel
por: Meng, Ziyuan, et al.
Publicado: (2016)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Long Noncoding RNA lncMUMA Reverses Established Skeletal Muscle Atrophy following Mechanical Unloading
por: Zhang, Zong-Kang, et al.
Publicado: (2018)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)

Analysis of Molecular Mechanism of Erxian Decoction in Treating Osteoporosis Based on Formula Optimization Model
por: Yang, Lang, et al.
Publicado: (2021)

A Loop‐Based and AGO‐Incorporated Virtual Screening Model Targeting AGO‐Mediated miRNA–mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice
por: Zhuo, Zhenjian, et al.
Publicado: (2020)

A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
por: Li, Fangfei, et al.
Publicado: (2017)

A newly identified lncRNA MAR1 acts as a miR‐487b sponge to promote skeletal muscle differentiation and regeneration
por: Zhang, Zong‐Kang, et al.
Publicado: (2018)

Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Mathematical algorithm–based identification of the functional components and mechanisms in depression treatment: An example of Danggui-Shaoyao-San
por: Gong, Wenxia, et al.
Publicado: (2022)

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
por: Ceresa, Brian P., et al.
Publicado: (2008)

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
por: Lv, Ning, et al.
Publicado: (2011)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study
por: Zhang, Xiaoling, et al.
Publicado: (2022)

Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial
por: Zhang, Chi, et al.
Publicado: (2019)

Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.
por: Cattoretti, G., et al.
Publicado: (1988)

An integrative method to decode regulatory logics in gene transcription
por: Yan, Bin, et al.
Publicado: (2017)

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Lee, Changro, et al.
Publicado: (2016)

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

A transcriptomic study of myogenic differentiation under the overexpression of PPARγ by RNA-Seq
por: He, Kan, et al.
Publicado: (2017)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
por: Shah, Ami N., et al.
Publicado: (2020)

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
por: Guan, Dandan, et al.
Publicado: (2022)

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells
por: Lim, Seung Taek, et al.
Publicado: (2018)

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
por: Yuan, Peng, et al.
Publicado: (2017)

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
por: Lamond, Nathan WD, et al.
Publicado: (2014)

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
por: OSAKO, TOMOFUMI, et al.
Publicado: (2015)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
por: Larionov, Alexey A.
Publicado: (2018)

Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
por: Yu, Tosol, et al.
Publicado: (2016)

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)

Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review
por: Sapna, FNU, et al.
Publicado: (2020)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
por: Yamaoka, Toshimitsu, et al.
Publicado: (2017)

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
por: Cortot, Alexis B., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2ttrp27diov6sd7itkubv68okk